Safety [clinicaltrials_resource:9defdc558bc229041002e49dfc139f79] - Clinical Trials - bio2rdf - TriplyDB

Safety [clinicaltrials_resource:9defdc558bc229041002e49dfc139f79]

Safety [clinicaltrials_resource:9defdc558bc229041002e49dfc139f79]

Clinical trial summary from the National Cancer Institute's PDQ® database

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]

http://bio2rdf.org/clinicaltrials_resource:9defdc558bc229041002e49dfc139f79

Safety [clinicaltrials_resource:9defdc558bc229041002e49dfc139f79]

Bio2RDF uri

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00091104]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety [clinicaltrials_resource:9defdc558bc229041002e49dfc139f79]

Clinical trial summary from the National Cancer Institute's PDQ® database

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]

http://bio2rdf.org/clinicaltrials_resource:9defdc558bc229041002e49dfc139f79

Bio2RDF identifier

9defdc558bc229041002e49dfc139f79

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials_resource

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials_resource:9defdc558bc229041002e49dfc139f79

http://www.w3.org/2001/XMLSchema#string

measure [clinicaltrials_vocabulary:measure]

Safety

http://www.w3.org/2001/XMLSchema#string

description

Clinical trial summary from the National Cancer Institute's PDQ® database

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials_resource:9defdc558bc229041002e49dfc139f79

http://www.w3.org/2001/XMLSchema#string

title

Safety

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]

label

Safety [clinicaltrials_resource:9defdc558bc229041002e49dfc139f79]

@en